IMO-2055: Interim Phase Ib data

Interim data from an open-label Phase Ib trial in 13 evaluable patients who had progressed on first-line chemotherapy showed that subcutaneous IMO-2055 plus Tarceva erlotinib and Avastin bevacizumab...